THE DEAL, AT A GLANCE
From the announcementProfound Therapeutics
What it doesProFound Therapeutics uses its ProFoundry platform and agentic AI to discover novel proteins, biomarkers and drug targets, here aimed at preeclampsia and eclampsia.From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗Who is involvedBacked by Gates FoundationFrom the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗What happenedProfound Therapeutics raised $20M Strategic Investment, announced 2026-08-27From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗Why it mattersProFound Therapeutics is positioned to apply its expanded human proteome platform to maternal-health drug discovery with strategic funding from the Gates Foundation.From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗Click a part to explore its evidence. Unsupported imagery is withheld rather than guessed.Original record source ↗
Profound Therapeutics · Financing Record
Explore source-linked visual explanations for Profound Therapeutics. Unsupported claims are withheld while source review continues.
Record 11198 · Recorded date: 2026-08-27
Explore company records →